Investigational drug · Phase 2
ERAS-007
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced or Metastatic Solid Tumors, Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
4
Any phase or sponsor naming "ERAS-007"
First trial start
2021
May 7, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ERAS-007", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced or Metastatic Solid Tumors
- Metastatic Colorectal Cancer
- Metastatic Pancreatic Ductal Adenocarcinoma
Approved drugs for the same conditions: Colorectal cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ERAS-007" as an intervention, largest first.
Erasca, Inc.Industry
NCT05039177 · 101 participants · Start Sep 20, 2021 · Primary completion Aug 15, 2025
Drug: ERAS-007; Encorafenib and 2 more · For: Metastatic Colorectal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma
Sites: Birmingham, Alabama; Duarte, California; Orange, California · 14 sites in all
Erasca, Inc.Industry
NCT04866134 · 85 participants · Start May 7, 2021 · Primary completion Jul 1, 2026
Drug: ERAS-007; ERAS-601 · For: Advanced or Metastatic Solid Tumors
Sites: Denver, Colorado; Sarasota, Florida; Nashville, Tennessee · 5 sites in all
- A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLCCompleted
Erasca, Inc.Industry
NCT04959981 · 24 participants · Start Sep 2, 2021 · Primary completion Apr 27, 2023
Drug: ERAS-007; ERAS-601 and 2 more · For: Advanced Non-squamous Non-small-cell Lung Cancer
Sites: Duarte, California; Orange, California; Santa Monica, California · 11 sites in all
Erasca, Inc.Industry
NCT05279859 · 0 participants · Start Mar 15, 2022 · Primary completion Mar 1, 2025
Drug: ERAS-007; ERAS-601 and 1 more · For: Acute Myeloid Leukemia
Sites: San Francisco, California; Dallas, Texas; Houston, Texas · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced or Metastatic Solid Tumors
- ERAS-601Phase 21 trial
Erasca, Inc. · Advanced or Metastatic Solid Tumors
- ETX-19477Phase 21 trial
858 Therapeutics, Inc. · Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer
- TAK-188Phase 21 trial
Takeda · Advanced or Metastatic Solid Tumors
- WTX-330Phase 21 trial
Werewolf Therapeutics, Inc. · Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.